Skip to content
Medical Health Aged Care

KFSHRC Performs World’s First Robotic Intracranial Tumor Resection … A New Era in Neurosurgery

King Faisal Specialist Hospital & Research Centre 3 mins read

RIYADH, Saudi Arabia, Oct. 20, 2025 (GLOBE NEWSWIRE) -- In a historic leap for robotic medicine, King Faisal Specialist Hospital and Research Centre (KFSHRC) in Riyadh has successfully performed the world’s first robotic intracranial tumor resection, a groundbreaking achievement that sets a new global standard in neurosurgical precision and recovery.

The surgery was conducted on a 68-year-old man experiencing severe headaches and loss of concentration and involved removing a 4.5-centimeter brain tumor using robotic arms. The patient was discharged fully conscious within 24 hours, a recovery time nearly four times faster than traditional brain surgeries.

Hospital officials credited the robotic tumor resection with minimizing surgical trauma and accelerating recovery. According to Dr. Homoud Aldahash, Consultant of Skull Base Tumors at KFSHRC, who performed the surgery, the robotic system allowed exceptional precision and control, enabling surgeons to navigate critical neurovascular structures with a high level of safety. “The patient’s same-day discharge, fully conscious and without complications, represents a new benchmark for neurosurgical innovation,” he added.

The one-hour surgery used robotic arms guided by a 3D optical system, allowing surgeons to operate with a clear and magnified view of the brain. The use of advanced image-guided navigation technology ensured precise removal of the tumor while protecting vital areas of the brain.

Dr. Majid Alfayyadh, CEO of KFSHRC, linked the milestone to the hospital’s ongoing transformation journey. “This achievement reflects KFSHRC’s growing role in shaping the future of global medicine,” he said. “It aligns perfectly with our vision, where innovation and patient-centered care define the future of healthcare.”

Before the advent of robotic neurosurgery, similar procedures required manual removal under a surgical microscope where precision depended heavily on human steadiness and visual clarity. Robotic systems now provide enhanced instrument stability, tremor elimination, and superior visualization, redefining global standards of safety and precision in neurosurgical care.

This landmark procedure adds to KFSHRC’s expanding portfolio of robotic surgical breakthroughs. The institution previously performed the world’s first robotic heart transplant and robotic liver transplant, earning international acclaim and solidifying its standing among the world’s leading centers for robotic and minimally invasive surgery.

As healthcare systems worldwide embrace automation and precision-guided surgery, KFSHRC’s latest success underscores its emergence as a global pioneer in next-generation medical innovation.

KFSHRC has been ranked first in the Middle East and North Africa and fifteenth globally among the world’s top 250 academic medical centers 2025. It was also recognized as the most valuable healthcare brand in the Middle East by Brand Finance 2025 and listed among Newsweek’s World’s Best Hospitals 2025, Best Smart Hospitals 2026, and Best Specialized Hospitals 2026, reaffirming its position as a global leader in innovation-driven patient care.

For more information, visit www.kfshrc.edu.sa or contact our media team at [email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/38efb792-747f-484a-b973-fd1f23c9a6e0


Primary Logo

More from this category

  • Medical Health Aged Care
  • 07/12/2025
  • 01:41
Takeda Pharmaceutical Company Limited

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline NEWARK,…

  • Medical Health Aged Care
  • 06/12/2025
  • 02:11
Arthur D. Little

Arthur D. Little and Vega IT Unveil Joint Venture for Digital Innovation

NEW YORK–BUSINESS WIRE– Arthur D. Little (ADL) and Vega IT today announced the formation of Axceler8 Solutions, a 50/50 joint venture created to design,…

  • Contains:
  • Medical Health Aged Care, Women
  • 05/12/2025
  • 10:11
Breast Cancer Trials

Bec’s Christmas wish amid cancer treatment

This Christmas, Bec’s wish is for her daughters to never face a breast cancer diagnosis like she has. “The only thing tougher than telling…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.